Accenture teams up with Bayer for speedier drug development

Bayer
Bayer joins a host of companies in trying to simplify and speed up the journey from bench to bedside by penning a deal with services company Accenture. (Bayer)

German pharma Bayer joins a host of companies in trying to simplify and speed up the journey from bench to bedside, penning a deal with services company Accenture to help do just that.

The New York-headquartered firm has signed up to help Bayer by using its so-called INTIENT Clinical platform.

How does it work? In a nutshell, it brings internal and external clinical data together with Oracle’s cloud-based tech into a single data management and warehousing platform, “creating actionable insights to accelerate drug development and improve patient outcomes,” according to the joint release. INTIENT works alongside the technology giant.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Bayer nabs new dealmaker—but after Monsanto, is there enough cash?

Mike Stapleton, a managing director in Accenture’s Life Sciences practice, said: “We are excited to work with Bayer to provide new insights on their clinical trials, so they can bring the important treatments they develop to patients faster and with the highest quality. The future of R&D is bright when leading organizations come together to solve for patients’ greatest needs.”

Financial details of the pact were not disclosed.

Suggested Articles

The BMJ warns that a “deluge of poor quality research [in COVID-19] is sabotaging an effective evidence-based response.”

Charles River Labs is revising down its guidance by a maximum of $215 million.

The ongoing COVID-19 uncertainty and the impact on its trials has caused PPD to pull its 2020 guidance.